Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
作者信息
Patel Shruti R, Neal Joel W
机构信息
Division of Medical Oncology, Department of Medicine, Stanford University, Stanford Cancer Institute, Palo Alto, CA, USA.
出版信息
Transl Lung Cancer Res. 2023 Jul 31;12(7):1631-1635. doi: 10.21037/tlcr-23-273. Epub 2023 Jun 12.
Abstract
摘要
相似文献
1
Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?辅助奥希替尼用于切除的表皮生长因子受体（EGFR）突变的非小细胞肺癌：是改变游戏规则的药物吗？
Transl Lung Cancer Res. 2023 Jul 31;12(7):1631-1635. doi: 10.21037/tlcr-23-273. Epub 2023 Jun 12.
2
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.ADAURA 研究结果的简明报告：奥希替尼用于早期 EGFR 突变型非小细胞肺癌术后患者。
Future Oncol. 2021 Dec 1;17(35):4827-4835. doi: 10.2217/fon-2021-0752. Epub 2021 Nov 1.
3
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.奥希替尼：完全切除的、早期、EGFR 突变阳性 NSCLC 中的研究。
Target Oncol. 2022 May;17(3):369-376. doi: 10.1007/s11523-022-00883-0. Epub 2022 Jun 17.
4
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.ADAURA研究中术后化疗的使用情况及结果：奥希替尼作为切除的EGFR突变型非小细胞肺癌的辅助治疗
J Thorac Oncol. 2022 Mar;17(3):423-433. doi: 10.1016/j.jtho.2021.10.014. Epub 2021 Nov 2.
5
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.III 期 ADAURA 试验中接受辅助奥希替尼治疗的表皮生长因子受体突变型非小细胞肺癌患者的健康相关生活质量结局。
Clin Cancer Res. 2022 Jun 1;28(11):2286-2296. doi: 10.1158/1078-0432.CCR-21-3530.
6
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.奥希替尼辅助治疗对切除的表皮生长因子受体（EGFR）突变阳性非小细胞肺癌患者的成本效益评估
Pharmacoecon Open. 2023 May;7(3):455-467. doi: 10.1007/s41669-023-00396-0. Epub 2023 Feb 22.
7
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.奥希替尼治疗可切除突变型非小细胞肺癌。
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
8
ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer.ADAURA研究：奥希替尼在表皮生长因子受体突变型非小细胞肺癌辅助治疗中的显著疗效
Oncol Ther. 2022 Jun;10(1):13-22. doi: 10.1007/s40487-022-00190-8. Epub 2022 Mar 16.
9
Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer.早期表皮生长因子受体突变的非小细胞肺癌治疗的最新进展与新见解
World J Clin Oncol. 2021 Oct 24;12(10):912-925. doi: 10.5306/wjco.v12.i10.912.
10
A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.西班牙关于早期表皮生长因子受体突变型非小细胞肺癌（NSCLC）临床管理的德尔菲共识小组：一项德尔菲共识小组研究。
Clin Transl Oncol. 2023 Jan;25(1):283-291. doi: 10.1007/s12094-022-02941-5. Epub 2022 Sep 27.
引用本文的文献
1
Predictors of survival and recurrence patterns following definitive chemoradiotherapy in stage III non-small cell lung cancer-a retrospective cohort study.III期非小细胞肺癌根治性放化疗后的生存预测因素及复发模式——一项回顾性队列研究
Transl Lung Cancer Res. 2025 Jun 30;14(6):1972-1985. doi: 10.21037/tlcr-24-840. Epub 2025 Jun 24.
本文引用的文献
1
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.辅助奥希替尼治疗 EGFR 突变型 IB-IIIA 期非小细胞肺癌：III 期随机 ADAURA 试验的更新结果。
J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31.
2
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review.循环肿瘤DNA在检测切除的非小细胞肺癌微小残留病中的作用：一项系统综述
Transl Lung Cancer Res. 2022 Dec;11(12):2588-2600. doi: 10.21037/tlcr-22-390.
3
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).三代 EGFR-TKI 耐药的机制及处理策略在晚期非小细胞肺癌中的应用（综述）。
Int J Oncol. 2021 Nov;59(5). doi: 10.3892/ijo.2021.5270. Epub 2021 Sep 24.
4
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.辅助阿特珠单抗治疗辅助化疗后切除的 IB-IIIA 期非小细胞肺癌（IMpower010）：一项随机、多中心、开放标签、III 期临床试验。
Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
5
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.奥希替尼治疗可切除突变型非小细胞肺癌。
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
6
MRD May Predict Relapse in NSCLC.MRD 可预测 NSCLC 复发。
Cancer Discov. 2020 Jul;10(7):OF7. doi: 10.1158/2159-8290.CD-ND2020-010. Epub 2020 May 28.
7
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.非小细胞肺癌：流行病学、筛查、诊断和治疗。
Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013.
8
Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival.年轻患者的肺癌：驱动基因突变率和脑转移率更高，但生存率更高。
J Glob Oncol. 2019 May;5:1-8. doi: 10.1200/JGO.18.00216.
9
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
10
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.早期和局部晚期非小细胞肺癌（NSCLC）：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222.
Zotero 插件